These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 30855644)

  • 21. Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment.
    Wong BL; Rybalsky I; Shellenbarger KC; Tian C; McMahon MA; Rutter MM; Sawnani H; Jefferies JL
    J Pediatr; 2017 Mar; 182():296-303.e1. PubMed ID: 28043681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deflazacort treatment of Duchenne muscular dystrophy.
    Biggar WD; Gingras M; Fehlings DL; Harris VA; Steele CA
    J Pediatr; 2001 Jan; 138(1):45-50. PubMed ID: 11148511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R; Reddy BVC; Malviya M; Sirari T; Attri SV; Patial A; Tageja M; Didwal G; Khandelwal NK; Saini AG; Saini L; Sahu JK; Dayal D; Sankhyan N
    J Pediatr Endocrinol Metab; 2021 May; 34(5):573-581. PubMed ID: 33838091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy.
    Nasomyont N; Keefe C; Tian C; Hornung L; Khoury J; Tilden JC; Hochwalt P; Jackson E; Rybalsky I; Wong BL; Rutter MM
    Osteoporos Int; 2020 Dec; 31(12):2449-2459. PubMed ID: 32676823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.
    Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.
    Biggar WD; Harris VA; Eliasoph L; Alman B
    Neuromuscul Disord; 2006 Apr; 16(4):249-55. PubMed ID: 16545568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up.
    Houde S; Filiatrault M; Fournier A; Dubé J; D'Arcy S; Bérubé D; Brousseau Y; Lapierre G; Vanasse M
    Pediatr Neurol; 2008 Mar; 38(3):200-6. PubMed ID: 18279756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth pattern trajectories in boys with Duchenne muscular dystrophy.
    Stimpson G; Raquq S; Chesshyre M; Fewtrell M; Ridout D; Sarkozy A; Manzur A; Ayyar Gupta V; De Amicis R; Muntoni F; Baranello G;
    Orphanet J Rare Dis; 2022 Jan; 17(1):20. PubMed ID: 35073949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy.
    Hawker GA; Ridout R; Harris VA; Chase CC; Fielding LJ; Biggar WD
    Arch Phys Med Rehabil; 2005 Feb; 86(2):284-8. PubMed ID: 15706555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional abilities, respiratory and cardiac function in a large cohort of adults with Duchenne muscular dystrophy treated with glucocorticoids.
    Schiava M; Lofra RM; Bourke JP; Díaz-Manera J; James MK; Elseed MA; Malinova M; Michel-Sodhi J; Moat D; Ghimenton E; Mccallum M; Díaz CFB; Mayhew A; Wong K; Richardson M; Tasca G; Eglon G; Eagle M; Turner C; Heslop E; Straub V; Bettolo CM; Guglieri M
    Eur J Neurol; 2024 Jun; 31(6):e16267. PubMed ID: 38556893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteoporotic Fractures and Vertebral Body Reshaping in Children With Glucocorticoid-treated Rheumatic Disorders.
    Ward LM; Ma J; Robinson ME; Scharke M; Ho J; Houghton K; Huber A; Scuccimarri R; Barsalou J; Roth J; Shenouda N; Matzinger MA; Lentle B; Jaremko JL; Koujok K; Watanabe Duffy K; Stein R; Sbrocchi AM; Rodd C; Miettunen PM; LeBlanc CMA; Larche M; Jurencak R; Cummings EA; Couch R; Cabral DA; Atkinson S; Alos N; Sykes E; Konji VN; Rauch F; Siminoski K; Lang B
    J Clin Endocrinol Metab; 2021 Nov; 106(12):e5195-e5207. PubMed ID: 34232311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
    Tian C; Wong BL; Hornung L; Khoury JC; Rybalsky I; Shellenbarger KC; Rutter MM
    Neuromuscul Disord; 2020 Jul; 30(7):599-610. PubMed ID: 32680651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10 m Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys.
    Stimpson G; Ridout D; Wolfe A; Milev E; O'Reilly E; Manzur A; Sarkozy A; Muntoni F; Cole TJ; Baranello G;
    J Neuromuscul Dis; 2024; 11(1):153-166. PubMed ID: 37980680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy.
    Ricotti V; Ridout DA; Scott E; Quinlivan R; Robb SA; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2013 Jun; 84(6):698-705. PubMed ID: 23250964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vertebral fractures in boys with Duchenne muscular dystrophy.
    Bothwell JE; Gordon KE; Dooley JM; MacSween J; Cummings EA; Salisbury S
    Clin Pediatr (Phila); 2003 May; 42(4):353-6. PubMed ID: 12800730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incident Vertebral Fractures and Risk Factors in the First Three Years Following Glucocorticoid Initiation Among Pediatric Patients With Rheumatic Disorders.
    LeBlanc CM; Ma J; Taljaard M; Roth J; Scuccimarri R; Miettunen P; Lang B; Huber AM; Houghton K; Jaremko JL; Ho J; Shenouda N; Matzinger MA; Lentle B; Stein R; Sbrocchi AM; Oen K; Rodd C; Jurencak R; Cummings EA; Couch R; Cabral DA; Atkinson S; Alos N; Rauch F; Siminoski K; Ward LM;
    J Bone Miner Res; 2015 Sep; 30(9):1667-75. PubMed ID: 25801315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone microarchitectural alterations in boys with Duchenne muscular dystrophy on long-term glucocorticoid treatment.
    Tung JY; Lam TP; Chan SH
    J Bone Miner Metab; 2021 Jul; 39(4):606-611. PubMed ID: 33400004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histomorphometry and Bone Matrix Mineralization Before and After Bisphosphonate Treatment in Boys With Duchenne Muscular Dystrophy: A Paired Transiliac Biopsy Study.
    Misof BM; Roschger P; McMillan HJ; Ma J; Klaushofer K; Rauch F; Ward LM
    J Bone Miner Res; 2016 May; 31(5):1060-9. PubMed ID: 26615086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy.
    Zacharin M; Lim A; Gryllakis J; Siafarikas A; Jefferies C; Briody J; Heather N; Pitkin J; Emmanuel J; Lee KJ; Wang X; Simm PJ; Munns CF
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2328-2342. PubMed ID: 33954789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.